Meet the Team
Nospharma was founded by dedicated scientists who, along with their team, bring a deep understanding of neuroscience, business and the pharmaceutical industry.
Anmol Nagpal, MSc
Chief Executive Officer & Co-Founder
Anmol is a neuroscientist-turned-entrepreneur, with over 10 years of experience in academia, healthcare and entrepreneurship. He was directly involved with the discovery that the anti-diabetic drug metformin, is a potential Fragile X Syndrome treatment. Metformin as a Fragile X Syndrome therapy is currently in Phase II/III clinical trials. Anmol has published his research in top peer-reviewed journals Nature Medicine, PNAS and Current Opinions in Genetics and Development.
In 2021, Anmol supported the Québec Government’s COVID-19 pandemic response as a Clinical Specialist at the McGill University Health Centre, where he helped establish rapid PCR testing workflows for SARS-CoV-2 in high-risk inpatients.
Since March 2023, Anmol has served as the Biotech Venture Associate and Validation Coach at District 3 Innovation, where he helps a portfolio of 25 biotech startups accelerate their commercialization potential in the biopharma, agri-tech, clean tech, food tech and biomaterials industries. At District 3, Anmol is responsible for strategic planning and execution of the biotechnology practice and acts as the liaison and animator for Québec biotech ecosystem.
Anmol earned his MSc in Neuroscience from the Faculty of Medicine and Health Sciences at McGill University, a Graduate Diploma in Business from Smith School of Business at Queen’s University, and a BASc in Cognitive Science and Philosophy from McGill University.
Dr. Derek Bowie, PhD
Chief Scientific Officer & Co-Founder
Dr. Derek Bowie is a neuroscientist and translational biologist who brings over 30 years of expertise in the fields of pharmacology and neurophysiology. He is Professor of Pharmacology and Therapeutics at McGill University and the Co-Director of the Cell Information Systems. Dr. Bowie is internationally recognized for his work on the biology of ion channels and has published his research in top peer-reviewed journals like Nature Structural Biology, Nature Communications, Neuron, and JNeurosci.
He is the recipient of the Canada Research Chair award in Receptor Pharmacology and has served on numerous national and international advisory panels including the International Brain Research Organization and International Union of Physiological Sciences. He also serves/has served on several editorial boards including the Journal of Physiology, European Journal of Neuroscience, Current Neuropharmacology, Channels, Current Opinion in Physiology and Frontiers in Neural Circuits.
Dr. Bowie earned his PhD at the University of London after completing his BSc at Strathclyde University in Scotland. He held postdoctoral roles at National Institutes of Health, the Université Louis Pasteur and Universität Zürich before taking a faculty position at Emory University. He joined McGill University as an Assistant Professor in 2002. He was recently invited as a Visiting Professor in Japan at the National Institutes for Physiological Sciences.
David Baker, MBA
Head of Corporate Development
David has over 30 years of executive, operational and commercial leadership experience in the biopharmaceutical industry. He has been directly involved with the commercialization of five medications with annual sales in excess of $1 billion each, including Adderall XR® and Vyvanse®, the two most successful ADHD brands.
Most recently, David was co-founder and CEO of Vallon Pharmaceuticals which went public on NASDAQ in 2021 and completed a merger with GRI Bio in 2023. Previously, David was the Chief Commercial Officer and interim CEO of Alcobra Ltd., a CNS specialty pharmaceutical company that developed medications for ADHD and Fragile X Syndrome. Alcobra merged with Arcturus Therapeutics (NASDAQ: ARCT) in 2017. Prior to Alcobra, he worked at Shire Plc for 10 years as Vice President of Commercial Strategy and New Business in the Neuroscience Business Unit, Global General Manager for Vyvanse® and Vice President, ADHD Marketing.
David began his career in life sciences at Merck & Co. where he worked for over a decade in marketing, sales, market research, and business development. He currently serves on the boards of GRI Bio (NASDAQ: GRI) and Devonian Health (TSXV: GSD; OTCQB: DVHGF).
David earned a BA in Economics and Computer Science from Duke University, and an MBA in Marketing, from Duke’s Fuqua School of Business.
Advisors
Our advisors bring decades of experience launching pharmaceutical products and building life science companies.
